(S) -Cdc7-IN-18

(S) -Cdc7-IN-18 is a potent inhibitor of CDC7. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells. (S) -Cdc7-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2020239107A1, compound 1-1) [1].

Product Specifications

CAS Number

[2562329-13-7]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/s-cdc7-in-18.html

Solubility

10 mM in DMSO

Smiles

O=C1C2=C(NC([C@@]3([H])N4CCC(CC4)C3)=N1)C5=C(C6=CNN=C6CCC5)S2

Molecular Formula

C19H21N5OS

Molecular Weight

367.47

References & Citations

[1]Gang Li, et al. Tetracyclines as Cdc7 inhibitors. Patent WO2020239107A1.|[2]Li Gang, et al. Tetracyclic compounds as cdc7 inhibitors. WO2020239107A1.